Malignant Neoplasms of Lip Oral Cavity and Pharynx Recruiting Phase 1 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03065387Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTreatment